Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and Placental Growth Factor (PlGF) in Preeclampsia among High Risk Pregnancies by Powers, Robert W. et al.
Soluble fms-Like Tyrosine Kinase 1 (sFlt1), Endoglin and
Placental Growth Factor (PlGF) in Preeclampsia among
High Risk Pregnancies
Robert W. Powers
1*, Arun Jeyabalan
1, Rebecca G. Clifton
2, Peter Van Dorsten
3, John C. Hauth
4,M a r kA .
Klebanoff
5, Marshall D. Lindheimer
6, Baha Sibai
7, Mark Landon
8, Menachem Miodovnik
9, for the Eunice
Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units
Network
"
1Department of Obstetrics, Gynecology and Women’s Health, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 2The
George Washington University Biostatistics Center, Washington, D.C., United States of America, 3Department of Obstetrics and Gynecology, Medical University of South
Carolina, Charleston, South Carolina, United States of America, 4Department of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine,
Birmingham, Alabama, United States of America, 5Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, United States
of America, 6Department of Obstetrics and Gynecology, University of Chicago School of Medicine, Chicago, Illinois, United States of America, 7Department of Obstetrics
and Gynecology, University of Tennessee School of Medicine, Memphis, Tennessee, United States of America, 8Department of Obstetrics and Gynecology, The Ohio State
University School of Medicine, Columbus, Ohio, United States of America, 9Department of Obstetrics and Gynecology, University of Cincinnati School of Medicine,
Cincinnati, Ohio, United States of America
Abstract
Background: Differences in circulating concentrations of antiangiogenic factors sFlt1 and soluble endoglin (sEng) and the
pro-angiogenic growth factor PlGF are reported to precede the onset of preeclampsia weeks to months in low-risk pregnant
women. The objective of this study was to investigate whether similar changes can be detected in pregnant women at high-
risk to develop the syndrome.
Methods: This study is a secondary analysis of the NICHD MFMU trial of aspirin to prevent preeclampsia in high-risk
pregnancies. Serum samples were available from 194 women with pre-existing diabetes, 313 with chronic hypertension, 234
with multifetal gestation, and 252 with a history of preeclampsia in a previous pregnancy. Samples collected across
pregnancy were analyzed in a blinded fashion for sFlt1, sEng and PlGF.
Results: The odds of developing preeclampsia were significantly increased among women with multiple fetuses for each 2-
fold elevation in sFlt1, sEng and the ratio of angiogenic factors (e.g. OR 2.18, 95% CI 1.46-3.32), and significantly decreased
for each 2-fold elevation in circulating PlGF (OR 0.50, 95% CI 0.30-0.82) between 7 and 26 weeks’ gestation. Cross-sectional
analysis of the angiogenic factors across gestation showed significant differences during the third trimester in women who
develop preeclampsia compared with appropriate controls in all high-risk groups. However, when data were examined in
relation to the gestational week when preeclampsia was diagnosed only sFlt1 was significantly higher 2 to 5 weeks before
the clinical onset of preeclampsia and only in women with previous preeclampsia.
Conclusions: The pattern of elevated concentrations of sFlt1 and sEng, and low PlGF in high-risk pregnant subjects who
develop preeclampsia is similar to that reported in low-risk pregnant women. However, differences in these factors among
high-risk women who do and do not develop preeclampsia are modest, and do not appear to be clinically useful predictors
in these high-risk pregnant women.
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Introduction
Preeclampsia is a pregnancy-specific syndrome affecting
approximately 5% of all pregnancies and is a leading cause of
maternal and fetal morbidity and mortality worldwide [1,2,3].
The incidence of preeclampsia is 3-5x greater in women with
chronic hypertension, diabetes present before conception,
multifetal gestation, and women who had preeclampsia in
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13263a previous pregnancy, and these populations are labeled
‘‘high-risk’’ [4].
The pathogenesis of preeclampsia remains incompletely eluci-
dated, however increased attention has been directed toward the
role of angiogenic and antiangiogenic factors including elevated
soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin
(sEng, a receptor for members of the TGFb superfamily), and
lower placental growth factor (PlGF) [5,6,7,8]. Concentrations of
these factors are significantly different in low-risk women who later
develop preeclampsia several weeks to months before clinical
manifestations of the disorder when compared with similar low-
risk women who have uncomplicated pregnancies [6,9]. However,
there is limited information regarding changes in these circulating
factors during pregnancies of high-risk patients who later develop
preeclampsia compared with similarly at risk women who do not
develop preeclampsia, and the ability of measured levels of sFlt1,
sEng and PlGF to predict preeclampsia in these high-risk patients.
Thegoalofthisstudywastoinvestigatewhetherdifferencesinthe
angiogenic factors sFlt1, sEng and PlGF in high-risk patients would
identify women who later develop preeclampsia in a manner similar
to reports in the literature regarding low-risk women. The high-risk
groups studied in this secondary analysis, chronic hypertensive, pre-
pregnancy diabetes, women with multifetal gestation, or previous
preeclampsia, were analyzed separately following a pre-analysis
hypothesis that the pathogenesis of preeclampsia for each group
may be different. This also permitted investigation of possible
differences in angiogenic factor levels between the groups.
Methods
Study Population
We performed a secondary analysis of serum samples obtained
during the Maternal-Fetal Medicine Units Network multicenter
randomized controlled trial of low-dose aspirin for the prevention
of preeclampsia in high-risk women [4]. This study, conducted
between May 1991 and June 1995, investigated four groups of
high-risk women: those with pre-gestational insulin treated
diabetes mellitus, chronic hypertension, multifetal gestation, and
those with a history of preeclampsia in a previous pregnancy. At
enrollment, subjects were offered participation in an ancillary
study that collected blood samples at three time points (study
entry, 24–28 and 34–38 weeks’ gestation). The ancillary study
started after the original trial was in progress and only a subset of
trial subjects participated. Subjects were included if they had at
least a study entry sample available for analysis.
The diagnosis of chronic hypertension required documentation
of antihypertensive-drug therapy by medical records or a blood
pressure while sitting of greater than or equal to 140/90 mmHg
taken on two occasions at least four hours apart, either before
pregnancy or during pregnancy, but prior to study entry and
before 20 weeks’ gestation. Multifetal gestation was documented
by ultrasound examination before enrollment. Previous pre-
eclampsia was defined as new-onset proteinuric hypertension as
determined by medical records or, in the absence of a record, an
oral history of preeclampsia that resulted in delivery before the
37
th gestational week. At the screening visit, all women underwent
urinary-protein testing by dipstick. If the test was 1+ or greater, a
24-hour urine sample was collected; women with values of 300mg
of protein per 24 hours were considered to have proteinuria.
Women with multi-fetal gestations were ineligible for the study if
they also had diabetes mellitus, chronic hypertension, or
proteinuria as defined above, as were women with a history of
preeclampsia and current proteinuria. Women with both diabetes
and hypertension were included in the diabetes group.
Institutional Review Board approval for the use of these stored
samples was obtained at both the University of Pittsburgh and
George Washington University. Subjects provided written in-
formed consent prior to enrolling in the initial study. Laboratory
assessment was completed at Magee-Womens Research Institute,
and data was subsequently linked and statistical assessment
completed at the George Washington University Biostatistics
Center.
Diagnosis of Preeclampsia
The diagnosis of preeclampsia for each of these high-risk groups
has been described previously [4]. In brief, preeclampsia was
defined in normotensive women with normal urinary protein
excretion at baseline as the development of hypertension plus one
of the following: proteinuria, thrombocytopenia, or pulmonary
edema. Hypertension was defined as a systolic and/or diastolic
blood pressure equal to or greater than 140 mmHg and 90 mmHg
respectively, on two occasions at least four hours apart and within
the same period (antepartum, intrapartum, postpartum). Protein-
uria was defined as excretion of $ 300mg of protein in a 24-hour
urine collection, or two dipstick-test results of $ 2+ (100 mg per
deciliter), the values recorded at least 4 hours apart, with no
evidence of urinary tract infection. Thrombocytopenia was
defined as a platelet count of less than 100,000 per cubic
millimeter. In women who had normal blood pressure but
proteinuria at baseline, the diagnosis of preeclampsia required
thrombocytopenia, or a serum aspartate aminotransferase con-
centration of $ 70 U per liter, or hypertension and either severe
headaches, epigastric pain, or worsening proteinuria (either five
times the baseline value or twice baseline if the baseline value
exceeded 5 g per 24 hours). In women who had hypertension but
no proteinuria at baseline, a diagnosis of preeclampsia required
the development of proteinuria or thrombocytopenia. A woman
was deemed to have preeclampsia if she had an eclamptic
convulsion or the HELLP syndrome, defined as hemolysis (serum
total bilirubin concentration of $1.2 mg per deciliter (20 mmol
per liter), a serum lactate dehydrogenase concentration of $ 600
U per liter, or hemolytic anemia as determined by the presence of
schistocytes on a peripheral smear), elevated serum concentration
of aspartate aminotransferase ($ 70 U per liter), and thrombo-
cytopenia. The records of all the women with apparent
preeclampsia, worsening hypertension, new-onset proteinuria, or
proteinuria at baseline ($ 1+) were reviewed independently by
three physicians who had to agree unanimously on the validity of
the designated outcomes, a policy designed to ensure diagnostic
consistency.
The clinical onset of preeclampsia was defined as the time at
which a patient met the criteria for preeclampsia as described
above rather than the time at which any single symptom first
occurred.
Laboratory methods
Serum samples were collected and aliquoted as part of the
Maternal-Fetal Medicine Units Network multicenter randomized
controlled trial of low-dose aspirin for the prevention of
preeclampsia in high-risk women [4]. Samples were collected
between June 1992 and December 1995, aliquoted, frozen and
stored at 280uC. Samples were thawed one time (74%) or thawed
two times (26%), and the storage time and handling of samples was
similar to that of other similar studies including the CPEP cohort.
Serum samples were assayed concurrently for sFlt1, sEng and
PlGF using commercially available immunoassay kits purchased
from R&D Systems (Minneapolis, MN). All kits utilized were from
the same manufacturing lot for each specific analyte, a policy
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performing dilutional parallelism and spike-recovery tests. Corre-
lations between the degree of sample dilution and measured
analytes were linear (r
2 .0.99, all). Calculated recoveries of excess
analytes were .94% for all. Measurements of each angiogenic
factor were performed in duplicate according to the manufactur-
er’s protocol. All laboratory analyses were performed by personnel
unaware of either pregnancy outcome or the high-risk group from
which the sera were obtained. In general, samples were diluted 1
to 5 for sFlt1 and sEng, and 1 to 2 for PlGF in order for the
samples to fall within the measurable range of the kit’s standard
curves. A minimal number of samples required re-analysis because
the results were outside of the range of the standard curve. Of the
total number of serum samples, 135 (5%) required re-assay for
sFlt1, 29 (0.9%) for sEng, and 33 (1.2%) for PlGF. The inter-assay
variability for each analyte was 10% for sFlt1, 11% for sEng and
7% for PlGF.
Statistical Methods
Data from all high-risk groups were analyzed separately.
Continuous variables were compared using the Wilcoxon rank-sum
test and categorical variables using the chi-square test. Change in the
concentration of a factor was calculated by taking the difference ofthe
value at study entry and the value obtained between 24 and 28 weeks
and dividing by the number of weeks between the two sample
collections. Logistic regression was used to calculate odds ratios and
the multivariable analysis included gestational age at sample
c o l l e c t i o n ,s m o k i n g ,m a t e r n a la g e ,r a c eo re t h n i cg r o u p ,b o d ym a s s
index and study treatment group (i.e., aspirin or placebo).
Data were also analyzed cross-sectionally, according to intervals of
gestational age and the number of weeks before the onset of
preeclampsia. In the intervals, when more than one sample existed
per woman, the earliest sample was used. All available samples were
used in the gestational age analysis whilea matched (1:1) pair analysis
was performed to evaluate differences in relation to the number of
weeks before the onset of preeclampsia. Specifically, in the paired
comparisons all available samples from subjects who developed
preeclampsia were distributed into time blocks according to when the
sample was collected in relation to the clinical onset of preeclampsia
for each subject (onset of clinically recognized preeclampsia is time 0).
Then a separate sample from a control subject from the same high-
risk group was matched within one week of the same gestational age
in weeks and by treatment group to the sample from the preeclampsia
subject. Data were log transformed and the difference was evaluated
using the Wilcoxon Signed Rank test.
All P values are two-tailed and a value less than 0.05 was
considered statistically significant. No adjustments were made for
multiple comparisons. Analyses were performed with the use of the
SAS software.
Results
Characteristics of the Study Subjects
A total of 2614 serum samples were available to assay. Eight
women did not have a study entry sample available for analysis
Table 1. Study Subject Information According to High-Risk Group.
Diabetes (n=194)
Chronic Hypertension
(n=313)
Multifetal Gestation
(n=234)
Previous Preeclampsia
(n=252)
Characteristic
Control
(n=148)
Preeclampsia
(n=46)
Control
(n=235)
Preeclampsia
(n=78)
Control
(n=195)
Preeclampsia
(n=39)
Control
(n=202)
Preeclampsia
(n=50)
Maternal age (years) 26662 6 662 9 673 0 662 5 662 6 672 4 652 5 66
Body-mass index (kg/m
2)2 8 672 7 683 3 693 4 692 6 672 9 682 8 683 0 69
Gestational age
at study entry (weeks)
17631 9 641 9 641 9 642 1 632 0 642 0 641 9 64
Primigravida, no. (%) 46 (31) 20 (43) 49 (21) 16 (21) 53 (27) 19 (49)* --- ---
Race or ethnic group,
no. (%)
*
Black 42 (28) 19 (41) 148 (63) 49 (63) 92 (47) 22 (56) 153 (76) 37 (74)
White 91 (61) 27 (59) 65 (28) 18 (23) 78 (40) 14 (36) 42 (21) 13 (26)
Hispanic/Other 15 (10) 0 (0) 22 (9) 11 (14) 25 (13) 3 (8) 7 (3) 0 (0)
Average blood pressure at
entry (mmHg)
112614/
67610
118615*/
70612
126615/
76612
132613*/
81611*
111611/
6469
11669*/
6769*
110611/
65610
115612*/
7069*
Smoked during pregnancy,
no. (%)
34 (23) 5 (11) 40 (17) 13 (17) 28 (14) 3 (8) 31 (15) 9 (18)
Aspirin treatment,
no. (%)
78 (53) 18 (39) 112 (48) 44 (56) 101 (52) 14 (36) 102 (50) 23 (46)
Gestational age at delivery
(weeks)
37623 6 623 8 623 6 63* 35633 5 623 8 623 7 62*
Gestational age at delivery
,37 weeks
46 (31) 23 (50)* 46 (20) 35 (45)* 122 (63) 28 (72) 30 (15) 16 (32)*
Onset of preeclampsia before
37 weeks’ gestation, no. (%)
--- 30 (65) --- 52 (67) --- 27 (69) --- 19 (38)
Infant birth weight (grams) 32886782 31626943 31206689 27976907* 23346607 24616458 31896642 31356729
Data are mean 6 standard deviation or N (%).
*: p,0.05 compared to group appropriate control.
doi:10.1371/journal.pone.0013263.t001
High Risk Preeclampsia
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13263and their fifteen subsequent samples were excluded. Therefore, a
total of 2,599 samples were available for this analysis (diabetes,
n=524; chronic hypertension, n=827; multifetal gestation,
n=574; and previous preeclampsia, n= 674) from 993 women
(diabetes, n=194; chronic hypertension, n=313; multifetal
gestation, n=234; and previous preeclampsia, n=252). The
original trial included 2,539 women so this analysis represents
39% of the women originally studied. Within each of the high-risk
groups, women in this analysis (i.e. women with samples) were
similar to women not included (i.e. without samples) for the
following characteristics: primigravida, smoking, maternal age and
body mass index. There were fewer African American and more
Caucasian in the diabetes group and fewer other and more
Caucasian in the multifetal group compared to women without a
sample. The gestational age at study entry was also slightly earlier
in women with samples in the multifetal gestation group compared
to women without a sample. Lastly, blood pressure at study entry
was slightly lower in women with chronic hypertension and slightly
higher in multifetal gestation compared to women without a
sample (data not shown).
The characteristics of the 993 study subjects are shown in
Table 1. The incidence of preeclampsia in the high-risk groups
was 46 of 194 (23.7%) for subjects with diabetes, 78 of 313 (24.9%)
for subjects with chronic hypertension, 39 of 234 (16.7%) for
subjects with multifetal gestations, and 50 of 252 (19.8%) for
subjects with previous preeclampsia. Within this cohort, only 40
subjects (4.0%) were identified as having the onset of preeclampsia
before 34 weeks’ gestation. The number of samples available
within each of the high-risk groups was too few to analyze by early
onset of preeclampsia (3 of the 4 risk groups had n,7).
Overall, there was no difference in maternal age, body mass
index, or gestational age at study entry between the preeclamptic
subjects within each high-risk group and their representative
controls. The preeclamptic subjects in each high-risk group
exhibited a modest but statistically significant higher average blood
pressure at study entry compared with their representative controls.
The original trial of low-dose aspirin in high-risk patients
indicated no effect of aspirin on outcome. In this study, the overall
incidence of preeclampsia was not significantly different in the
aspirin and placebo treated groups (20% versus 23%, p=0.31).
Table 2. Odds Ratios for Preeclampsia According to Circulating Angiogenic Factors Measured in Samples Collected at Study
Entry.*
Diabetes
Controls
(N=148)
Preeclampsia
(N=46)
Unadjusted OR
[95% CI]
Adjusted OR
[95% CI] {
sFlt1 (ng/ml) 3.6062.02 3.7562.33 0.98 [0.64,1.51] 0.98 [0.63,1.53]
sEng (ng/ml) 5.3161.58 5.7562.29 1.62 [0.74,3.54] 1.66 [0.70,3.92]
PIGF (pg/ml) 151.146144.55 156.746147.51 1.02 [0.78,1.32] 0.59 [0.36,0.95]
sFlt1 + sEng/PIGF 124.946135.34 124.366111.64 1.03 [0.80,1.32] 1.61 [1.07,2.48]
Chronic Hypertension
Controls
(N=235)
Preeclampsia
(N=78)
Unadjusted OR
[95% CI]
Adjusted OR
[95% CI] {
sFlt1 (ng/ml) 3.6863.66 3.8362.91 1.09 [0.79,1.49] 1.16 [0.83,1.63]
sEng (ng/ml) 5.5865.73 6.0563.60 1.51 [0.96,2.39] 1.60 [1.01,2.57]
PIGF (pg/ml) 222.546236.67 191.616154.19 0.92 [0.74,1.13] 0.96 [0.71,1.29]
sFlt1 + sEng/PIGF 96.656214.75 123.716216.91 1.13 [0.94,1.36] 1.13 [0.90,1.41]
Multifetal Gestation
Controls
(N=195)
Preeclampsia
(N=39)
Unadjusted OR
[95% CI]
Adjusted OR
[95% CI] {
sFlt1 (ng/ml) 5.9562.47 7.3365.42 1.55 [0.93,2.68] 2.07 [1.15,3.89]
sEng (ng/ml) 7.0462.70 8.5464.50 2.14 [1.14,4.05] 2.98 [1.44,6.36]
PIGF (pg/ml) 554.736388.10 386.106318.17 0.61 [0.44,0.82] 0.50 [0.30,0.82]
sFlt1 + sEng/PIGF 40.37643.20 75.31667.62 1.80 [1.35,2.44] 2.18 [1.46,3.32]
Previous Preeclampsia
Controls
(N=202)
Preeclampsia
(N=50)
Unadjusted OR
[95% CI]
Adjusted OR
[95% CI] {
sFlt1 (ng/ml) 3.3261.84 3.1661.72 0.86 [0.60,1.32] 0.96 [0.61,1.52]
sEng (ng/ml) 5.5264.93 5.6062.71 1.25 [0.72,2.12] 1.41 [0.80,2.46]
PIGF (pg/ml) 231.586218.94 191.356159.20 0.89 [0.72,1.11] 0.93 [0.67,1.36]
sFlt1 + sEng/PIGF 100.706207.02 122.376186.63 1.13 [0.92,1.38] 1.15 [0.83,1.56]
*Data are presented as mean 6 standard deviation. OR denotes odds ratio, CI confidence interval. Odds ratios represent the odds of developing preeclampsia for a two-
fold increase of the factor among preeclamptic subjects compared to controls.
{Odds ratios were adjusted for gestational age at sample collection, smoking, maternal age, race or ethnic group, body mass index and treatment group.
doi:10.1371/journal.pone.0013263.t002
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addition, there was no difference in the concentrations of sFlt1,
sEng and PlGF between women who were in the aspirin treatment
group and those in the placebo group (p$0.05). Formal tests for
interaction between treatment group and the markers were not
significant. For these reasons, aspirin treated and placebo groups
were combined for these analyses.
Angiogenic Factors at Study Entry
Subjects provided blood samples at the time of study entry (7–26
weeks’gestation). Samples wereobtained from allwomenbeforethe
onset of clinical signs of preeclampsia. The concentration of sFlt1,
sEng and PlGF were all statistically significantly higher at study
entryinthewomenwithmultifetal gestationcomparedwith subjects
with pre-existing diabetes, chronic hypertension and previous
preeclampsia (p,0.0001 for all, data not shown). In addition, the
concentration of PlGF was significantly lower in the diabetic
subjects compared with PlGF in the chronic hypertensive and
previous preeclampsia high-risk groups (p,0.001, data not shown).
We investigated whether differences in the angiogenic factors at
study entry were associated with the subsequent development of
preeclampsia. The odds for developing preeclampsia were
significantly increased 2 to 3 fold for each 2-fold elevation in the
concentration of sFlt1, sEng and the ratio of combined angiogenic
factors (sFlt1+ sEng/PlGF) at study entry among women with
multifetal gestations who later developed preeclampsia (Table 2).
In addition, the odds of developing preeclampsia were significantly
decreased by half for each 2-fold elevation in maternal circulating
PlGF at study entry among women with multifetal gestations and
diabetes (Table 2). The odds of developing preeclampsia was
significantly increased by 60% for each 2-fold elevation in
circulating sEng at study entry among subjects with chronic
hypertension, and for each 2-fold elevation in the angiogenic
factor ratio among subjects with diabetes (Table 2). Conversely,
none of the factors analyzed or their ratio at study entry were
associated with an increased odds of developing preeclampsia
among the subjects with previous preeclampsia.
Concentration of Angiogenic Factors Across Gestation
We next investigated whether the change in each factor between
the sample collected at study entry and the sample collected at visit
2 (between 24 and 28 weeks’ gestation) identified women at an
increased risk of later developing preeclampsia. A total of 790 of
the 993 women had samples collected during these two time
Table 3. Odds Ratios for Preeclampsia According to the Change per Week in Circulating Angiogenic Factors between Study Entry
and Second Study visit.*
Diabetes
Controls
(N=130)
Preeclampsia
(N=37)
Adjusted OR
[95% CI] {
Change in sFlt1 (ng/ml) 0.0460.17 0.0760.57 1.14 [0.34, 4.84]
Change in sEng (ng/ml) 0.0860.23 0.2760.44 4.58 [1.31, 17.5]
Change in PIGF (pg/ml) 33.88638.92 33.09657.49 0.99 [0.90, 1.08]
Change in sFlt1 + sEng/PIGF 28.39612.21 0.33625.01 1.10 [1.04, 1.19]
Chronic Hypertension
Controls (N=187) Preeclampsia (N=62) Adjusted OR [95% CI] {
Change in sFlt1 (ng/ml) 0.0761.04 0.2560.49 1.62 [0.94, 3.02]
Change in sEng (ng/ml) 0.7067.01 0.4961.24 0.99 [0.84, 1.05]
Change in PIGF (pg/ml) 32.88663.28 28.97643.72 0.98 [0.90, 1.04]
Change in sFlt1 + sEng/PIGF 20.54668.50 12.76665.88 1.01 [0.99, 1.02]
Multifetal Gestation
Controls (N=154) Preeclampsia (N=33) Adjusted OR [95% CI] {
Change in sFlt1 (ng/ml) 0.1560.49 0.4860.81 4.91 [1.95, 16.1]
Change in sEng (ng/ml) 0.2760.59 0.7561.39 2.82 [1.51, 5.77]
Change in PIGF (pg/ml) 54.456114.54 24.15677.87 0.95 [0.90, 1.00]
Change in sFlt1 + sEng/PIGF 21.2366.90 5.52620.29 1.10 [1.05, 1.17]
Previous Preeclampsia
Controls (N=153) Preeclampsia (N=34) Adjusted OR [95% CI] {
Change in sFlt1 (ng/ml) 0.0760.28 0.2761.02 2.58 [1.14, 9.06]
Change in sEng (ng/ml) 0.0660.54 0.2361.21 1.48 [0.91, 2.62]
Change in PIGF (pg/ml) 44.18655.16 33.13631.13 0.98 [0.87, 1.08]
Change in sFlt1 + sEng/PIGF 26.70646.77 21.99655.61 1.01 [0.99, 1.02]
*Data are presented as mean 6 standard deviation. OR denotes odds ratio, CI confidence interval.
{Odds ratios were adjusted for gestational age and concentration of sample at visit 1, smoking, maternal age, race or ethnic group, body mass index, and treatment
group. Odds ratios for sFlt1, sEng and sFlt1+Endo/PIGF represent the odds of developing preeclampsia compared to control subjects for each 1-unit increase of the
factor, and the odds ratio for PlGF represents a 10-unit increase of the factor among preeclamptic subjects compared to controls.
doi:10.1371/journal.pone.0013263.t003
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increased for each 1-unit increase in the change in circulating sFlt1
among the multifetal gestation and previous preeclampsia high-
risk groups (Table 3). In addition, the odds of developing
preeclampsia were significantly increased for each 1-unit increase
in the change in sEng among the diabetes and multifetal gestation
high-risk groups. Finally, the odds of developing preeclampsia
were significantly increased for each 1-unit increase in the change
in the angiogenic factor ratio among the diabetes and multifetal
high-risk groups (Table 3). While these odds ratios are statistically
significant, a 1-unit difference in these factors represents a sizable
change as evidenced by the values reported in Table 3.
We also investigated the differences in the maternal concentra-
tion of each factor between subjects who developed preeclampsia
and their representative controls cross-sectionally within defined
intervals of gestational age. In all diagnostic groups, there were
modest but statistically significant differences in at least one factor
between the subjects who developed preeclampsia and their
representative controls at some time in pregnancy. There were no
significant differences in sFlt1 between women who developed
preeclampsia with pre-existing diabetes compared with control
subjects at any stage of gestation (Figure 1A). The concentration of
sFlt1 was significantly higher at 26 to 30 weeks’ gestation among
chronic hypertension (Figure 1B) and multifetal gestation
(Figure 1C) subjects who developed preeclampsia. In addition,
sFlt1 was significantly higher at 31 to 35 weeks’ gestation in
multifetal gestation (Figure 1C) subjects who developed pre-
eclampsia. The maternal concentration of sFlt1 tended to be
higher at 36 weeks to term among the previous preeclampsia
subjects with preeclampsia (p=0.05; Figure 1D).
The concentration of sEng was significantly higher at 26 to 30
weeks in diabetic (Figure 2A), chronic hypertension (Figure 2B)
and previous preeclampsia (Figure 2D) subjects who later
developed preeclampsia. In addition, sEng was significantly higher
at 31 to 35 weeks’ gestation in multifetal gestation (Figure 2C) and
previous preeclampsia (Figure 2D) subjects who later developed
preeclampsia, and sEng tended to be higher at 36 weeks to term
among the previous preeclampsia subjects with preeclampsia
(p=0.09; Figure 2D).
The concentration of maternal serum PlGF across gestation is
shown in Figure 3. The maternal concentration of PlGF was
significantly lower at 31 to 35 weeks’ gestation in women with
previous preeclampsia and who developed preeclampsia
(Figure 3D). Similarly, PlGF was significantly lower at 26 to 30
weeks and 31 to 35 weeks’ gestation in multifetal gestation patients
with preeclampsia (Figure 3C). Surprisingly, there were no
Figure 1. Maternal serum sFlt1 across gestation in women with pre-existing diabetes (A), chronic hypertension (B), multifetal
gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are subjects who developed preeclampsia. The
number above each box indicates the number of samples. The filled black circles are the median, the open circles are the 90th and 10th percentiles,
and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group. Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g001
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preeclampsia compared with control subjects among the women
with pre-existing diabetes or chronic hypertension at any stage of
gestation (Figures 3A and 3B).
Concentration of Angiogenic Factors in Relation to the
Clinical Onset of Preeclampsia
We next investigated whether the maternal concentration of the
angiogenic factors was different between subjects who developed
preeclampsia compared with controls among the four high-risk
groups in relation to the clinical onset of the syndrome. Box and
whisker plots of matched samples according to the clinical onset of
preeclampsia (time 0) for each separate high-risk group are shown
in Figures 4 (sFlt1), Figures 5 (sEng) and Figures 6 (PlGF).
Maternal sFlt1 was significantly elevated 2 to 5 weeks before the
onset of preeclampsia in the subjects with previous preeclampsia,
as well as within 1 week of the clinical onset of preeclampsia
(Figure 4D). However, sFlt1 concentrations were not significantly
elevated before the onset of preeclampsia in any of the other high-
risk groups (Figures 4A, B and C). Similarly, the concentration of
maternal sEng was not significantly elevated in any of the high-risk
groups immediately before or close to the onset of preeclampsia
compared with samples from gestational age matched controls
(Figures 5A, B, C and D). Of note, there was a modest but
statistically significant elevation in sEng at $18 weeks before the
onset of preeclampsia among the chronic hypertension patients
compared with their matched controls. Lastly, the concentration
of maternal PlGF was not significantly lower among any of the
high-risk groups (Figures 6A, B, C and D) except at 6–9 weeks in
the chronic hypertensive group (Figure 6B). In addition, the ratio
of the angiogenic factors was not different in any of the high-risk
groups before the onset of preeclampsia compared with samples
from gestational age matched controls (data not shown).
Discussion
There has been considerable interest in the role and possible
predictive value of the circulating angiogenic factors sFlt1, sEng
and PlGF for preeclampsia as evidenced by a growing literature
since 2003. Most studies have focused on low-risk populations
while very few have evaluated the utility of these factors in high-
risk pregnant populations, and the latter reports are limited in size
or have evaluated subjects with different reasons for being
classified high-risk together [7,8,9,10,11,12]. In our study,
maternal circulating sFlt1, sEng and PlGF were significantly
higher at study entry in subjects with multifetal gestations
Figure 2. Maternal serum sEng across gestation in women with pre-existing diabetes (A), chronic hypertension (B), multifetal
gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are subjects who developed preeclampsia. The
number above each box indicates the number of samples. The filled black circles are the median, the open circles are the 90th and 10th percentiles,
and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group. Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g002
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lower in the diabetic subjects. The odds of developing preeclamp-
sia were significantly increased for each 2-fold elevation in sFlt1,
sEng and the angiogenic factor ratio, and were significantly
decreased for each 2-fold elevation in PlGF at study entry in
subjects with multifetal gestations. Similarly, the odds of
developing preeclampsia are significantly decreased by half for
each 2-fold elevation in maternal PlGF among diabetics, and
increased by 60% for each 2-fold elevation in sEng and the
angiogenic factor ratio at study entry for subjects with chronic
hypertension and diabetes respectively. While these odds ratios are
statistically significant, the confidence intervals associated with
them are wide, and the magnitude of the elevation in the
angiogenic factors in early pregnancy is large, which does not lend
confidence to the possibility of these factors individually as useful
predictors of preeclampsia in these high-risk groups. However,
these data do not preclude the possible utility of these factors in a
multiple marker screen for the prediction of preeclampsia.
We also observed that the change in sFlt1 and sEng, and the
change in the ratio of the angiogenic factors between study entry
(7–26 weeks’ gestation) and the second study visit (24–28 weeks’
gestation) was associated with a significant increase in the odds of
developing preeclampsia among these high-risk populations.
These data are similar to that previously reported among low-
risk patients, such that women who developed preeclampsia were
more likely to show greater sequential changes in sFlt1 and sEng in
early pregnancy, and these changes were most pronounced in
preterm preeclampsia [13]. These data suggest that perhaps the
absolute concentration of these antiangiogenic factors is not as
important as the relative change in these factors within an
individual in early pregnancy, and that similar pathophysiologic
mechanisms may be at work in low-risk and high-risk populations.
While these data are intriguing, the absolute change in these
factors associated with an increased risk of preeclampsia is large.
We observed that sFlt1 and sEng were statistically higher, and
PlGF was significantly lower at 26 to 30 weeks’ gestation or later
during pregnancy in subjects who later develop preeclampsia in
some but not all of the four high-risk groups. In addition, we
observed that there were relatively few significant differences in the
concentration of these angiogenic factors that precede the onset of
the clinical syndrome of preeclampsia. In most cases, however,
even when the differences are not significant, the relationship of
mean values of these angiogenic factors is similar to that observed
in low-risk women with higher sFlt1 and sEng and lower PlGF in
women who later develop preeclampsia suggesting these factors
may play a role in the pathophysiology of preeclampsia in these
Figure 3. Maternal serum PlGF across gestation in women with pre-existing diabetes (A), chronic hypertension (B), multifetal
gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are subjects who developed preeclampsia. The
number above each box indicates the number of samples. The filled black circles are the median, the open circles are the 90th and 10th percentiles,
and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group. Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g003
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or their ratio make it unlikely they will be clinically useful as
individual predictive markers of preeclampsia in these high-risk
groups.
Among low-risk pregnant patients, sFlt1 has been reported to be
significantly elevated by 33 to 36 weeks’ gestation and .5 weeks
before the clinical onset of preeclampsia [10]. Similarly, maternal
concentrations of sEng are significantly elevated at 25 to 28 weeks’
gestation and 9 to 11 weeks before clinical onset of preterm
preeclampsia, and 33 to 36 weeks’ gestation and 9 to 11 weeks
before the clinical onset of term preeclampsia [9]. Maternal
concentrations of PlGF are also reported to be significantly lower
by 13 to 20 weeks’ gestation among women who later develop
preeclampsia compared with similar low-risk control subjects [10].
In contrast to low-risk subjects, there has been limited investigation
of the differences in these angiogenic factors across pregnancy
among high-risk subjects. Moore Simas et al. evaluated the
predictive value of maternal sFlt1 and PlGF between 22 and 36
weeks’ gestation in a combination of several high-risk populations
including patients with chronic hypertension and pre-gestational
diabetes [14]. This study reported that mean serum sFlt1 and
sFlt1/PlGF ratio were higher at 22 weeks’ gestation in subjects
who developed early onset preeclampsia (,34 weeks) compared
with uncomplicated controls, and that serum sFlt1 was signifi-
cantly higher after 31 weeks’ gestation in subjects with late onset
preeclampsia (.34 weeks). The authors conclude that these
angiogenic factors may be predictive of preeclampsia in high-risk
populations. However, this study is limited by a small sample size,
with 12 preeclamptic subjects total, 5 with early onset and 7 with
late onset preeclampsia; as well as a significantly mixed population
of high-risk groups (all 5 early onset preeclamptic subjects had
chronic hypertension, 2 with pre-gestational diabetes, 1 with renal
disease, and 2 with previous preeclampsia) making it difficult to
conclude the significance of these factors within any single high-
risk group. A study by the same group also reported that maternal
serum sFlt1 and PlGF are significantly elevated in subjects with
multifetal gestations as early as 22 weeks’ gestation [15]. These
data are similar to the data reported in this study, as well as our
finding that sEng is also significantly higher in all pregnant women
with multifetal gestations. The explanation for the elevated
angiogenic factors in women with multifetal gestations is likely
related to the increased placental mass, however we lack sufficient
information to provide a complete explanation. This same
explanation was also proposed by Maynard et al. as well as
Figure 4. Maternal serum sFlt1 by clinical onset of preeclampsia matched to control samples in women with pre-existing diabetes
(A), chronic hypertension (B), multifetal gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are
subjects who developed preeclampsia. The number above each box indicates the number of samples. The filled black circles are the median, the
open circles are the 90th and 10th percentiles, and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group.
Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g004
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placental mass in multifetal gestations (r=0.62, p=0.0002) [15].
In addition, a recent study by Sibai et al. investigated the
predictive value of maternal sFlt1 and PlGF between 12 to 19
weeks and 24 to 28 weeks’ gestation among 704 patients with
previous preeclampsia and/or chronic hypertension (14.7% had
both conditions) [16]. The authors reported that PlGF concen-
trations were significantly lower at baseline and sFlt1 concentra-
tions were higher at 24 to 28 weeks’ gestation in subjects who later
developed preeclampsia, and these differences were most notice-
able among subjects who developed preeclampsia before 27 weeks’
gestation. However, overall these differences were modest, and the
sensitivities and positive predictive values were low suggesting that
the clinical utility of these markers is limited.
In general, the patterns of angiogenic factor concentrations
across pregnancy in this study (i.e. elevated sFlt1 and sEng and low
PlGF among subjects who develop preeclampsia) are similar to
those presented in studies of low-risk pregnant women. However,
differences in these angiogenic factors between high-risk women
who develop preeclampsia compared with high-risk women who
do not develop preeclampsia appear more modest, similar to the
data presented by Sibai et al [16]. What then might be the possible
reasons for these differences between studies involving low-risk
pregnant women compared with high-risk pregnant women? One
notable technical difference is a change in the formulation of the
commercial kit for the measurement of sFlt1. Most prior studies
and our study used the ELISA kit from the same company (R&D
Systems; Minneapolis, MN). A formulation change in this kit made
since the publication of several of the prior studies resulted in
higher measured concentrations of sFlt1 than reported previously
among low-risk pregnant women. However, the formulation of the
commercial ELISA kits for sEng and PlGF have not changed, and
the overall pattern of maternal serum sFlt1 concentrations in high-
risk women is similar to that of low-risk women.
In this study we decided a priori to analyze these high-risk
groups separately. Preeclampsia is a heterogeneous condition and
it is quite likely that the path to preeclampsia might be different
between these disparate high-risk conditions. Despite this,
limitations in sample size are an unlikely explanation since the
number of high-risk subjects within each group in this study is
considerably greater than that presented in other studies of high-
risk subjects, and the number of samples in this study was in many
cases as numerous as those used in studies of low-risk women.
However, despite the large number of subjects and samples in this
Figure 5. Maternal serum sEng by clinical onset of preeclampsia matched to control samples in women with pre-existing diabetes
(A), chronic hypertension (B), multifetal gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are
subjects who developed preeclampsia. The number above each box indicates the number of samples. The filled black circles are the median, the
open circles are the 90th and 10th percentiles, and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group.
Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g005
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severity criteria (,34 weeks’ gestation) which is when the most
pronounced differences in these angiogenic factors appear among
low-risk subjects, because of an insufficient number of these
preterm subjects in each of the high risk groups [9]. An additional
limitation of this study is the fact that the original parent study was
not designed to predict preeclampsia. However, despite these
limitations, all samples in this study were analyzed in a blinded
fashion, the inter-assay variability for the measurement of each
angiogenic factor was within acceptable limits and similar to that
presented in other studies, the overall variability of the data
particularly for sEng was low and similar to that presented in other
studies, the majority of samples were thawed only one time (74%)
or thawed two times (26%), and the storage time and handling of
samples was similar to that of other studies including the CPEP
cohort which reported similar values to those reported in this study
[13] [17]. Importantly, aspirin was found to have no significant
effect on the concentration of any of the angiogenic factors. It is
possible that difficulty in determining the clinical diagnosis of
preeclampsia in subjects with chronic hypertension and especially
these and other subjects with preexisting proteinuria may have
affected the results of this study. However, the diagnosis of
preeclampsia in these subjects was critically evaluated by chart
reviews in the initial parent study. In addition, this limitation
provides additional rationale for maintaining separate diagnostic
groups. The clinical diagnosis of preeclampsia in patients with
previous preeclampsia or multifetal gestations was not confounded
by preexisting conditions, yet even these high-risk groups had only
modest differences in the measured angiogenic factors.
In conclusion, we have observed that the maternal concentra-
tion of the angiogenic factors sFlt1, sEng and PlGF are
significantly higher among women with multifetal gestations
compared with other high-risk groups including: pre-existing
diabetes, chronic hypertension and previous preeclampsia. The
sequential change in sFlt1, sEng and the ratio of these angiogenic
factors in early pregnancy is associated with a significant increase
in the odds of developing preeclampsia. However, these sequential
changes need to be large. Cross-sectional analysis of maternal
sFlt1, sEng and PlGF show modest significant differences of at
least one of these factors during the third trimester in women who
develop preeclampsia in all high-risk groups. Only sFlt1 was
significantly higher 2 to 5 weeks before the clinical onset of
preeclampsia in women with previous preeclampsia. The signif-
icant differences in sFlt1, sEng and PlGF evident in women at
Figure 6. Maternal serum PlGF by clinical onset of preeclampsia matched to control samples in women with pre-existing diabetes
(A), chronic hypertension (B), multifetal gestation (C), and previous preeclampsia (D). Open boxes are controls and shaded boxes are
subjects who developed preeclampsia. The number above each box indicates the number of samples. The filled black circles are the median, the
open circles are the 90th and 10th percentiles, and the top and bottom lines of the box are the 75
th and 25
th percentiles of the data for each group.
Statistical significance is indicated by p values.
doi:10.1371/journal.pone.0013263.g006
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the pathophysiology of preeclampsia. However, we conclude that
the concentration of these circulating angiogenic factors is unlikely
to be useful in predicting preeclampsia in these high-risk
populations.
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